Bruce A Feinberg, DO

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

Sarah S Mougalian, MD

Jingchuan Zhang, PhD

Talia Miller, MSW, MPH

Marjorie E Zettler, PhD, MPH

Bruce A Feinberg, DO

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways

Counterpoint

Understanding Provider Perceptions Is Key to Utilization and Uptake of CAR-T Therapy

04/17/2018

Bruce A Feinberg, DO

Chadi Nabhan, MD, MBA, FACP

The potential impact of chimeric antigen receptor T-cell (CAR-T) therapies should not be underestimated, nor should their complexity. There is much to consider when reprogramming patients’ own immune cells. As most...

The...

04/17/2018

Journal of Clinical Pathways

From the Field

Mock Clinical Pathways: Exploring the Process of Developing a Pathway for Metastatic Breast Cancer

02/15/2018

Bruce A Feinberg, DO

Chadi Nabhan, MD, MBA, FACP

Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care delivery, allowing for cost reduction as well as more predictable, measurable, and accountable outcomes. At the 2nd Annual...

Abstract: Clinical...

02/15/2018

Journal of Clinical Pathways